Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings showed a 39.6% growth in net product revenues ...

Here I use Interpublic Group as a case study, scrutinizing it under elements of an active portfolio management framework. The business produces modestly attractive economics, but is in an earnings ...

Last week, the U.S. Supreme Court heard a case debating whether it's legal to restrict content moderation on social media platforms like Facebook, YouTube and X. Those companies should anticipate a ...

Shares of Bristol Myers Squibb declined after the company announced that the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten) failed. The phase III study was evaluating ...

A new academic study said people are diverting stock investments into legal gambling. The researchers founded that household investments are reduced by roughly $2 for ever dollar wagered. This has had ...

GRI Bio, Inc.’s GRI shares plummeted 36.9% on April 1 after the company announced the pricing of a public offering of stock of $5 million. Earlier in the day, the stock surged after the company ...

NeuroPace, Inc. (NASDAQ:NPCE) released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic ...

Recent survey data suggests that investor apprehension regarding a potential stock market crash could actually serve as a boost for stocks. What Happened: The survey revealed that more than half of ...

Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with depression in a study. The drug, called navacaprant, was no better than a ...